



PRESS RELEASE

Collectis Announces Conference Call to Discuss UCART19 Development Collaboration with Pfizer and Servier

December 3, 2015 – Collectis (Alternext: ALCLS – Nasdaq: CLLS) will host a conference call with Pfizer Inc. (PFE) and Servier on Monday, December 7, 2015 at 8:00 a.m. Eastern Time to discuss their previously announced UCART19 development collaboration.

UCART19 is a TALEN® gene-edited allogeneic Chimeric Antigen Receptor T-Cell (CAR-T) immunotherapy developed by Collectis. On November 19, 2015, Servier exercised its worldwide licensing option with Collectis to UCART19 and entered into a global UCART19 license and collaboration agreement with Pfizer.

Conference Call Information

Collectis, Pfizer and Servier management will host a conference call on Monday, December 7, 2015 at 8:00 a.m. ET to discuss UCART19 three-party collaboration.

Dial-In Numbers:

Live Participant Dial-In (Toll-Free US & Canada): 877-407-3104

Live Participant Dial-In (International): +1 201-493-6792

Replay Information:

Conference ID #: 13625168

Replay Dial-In (Toll Free US & Canada): 877-660-6853

Replay Dial-In (International): +1 201-612-7415

Expiration Date: 12/21/15

Webcast URL (Archived for 12 months):

<http://collectis.equisolvewebcast.com/12-7-UCART19>

About Collectis

Collectis is a biopharmaceutical company focused on developing immunotherapies based on gene edited CAR T-cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Collectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN® products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its life-science-focused, pioneering genome-engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.collectis.com

Talking about gene editing? We do it.
TALEN® is a registered trademark owned by the Collectis Group.

For further information, please contact:

Media contacts

Jennifer Moore, VP Communications
Phone: +1 917-580-1088
email: media@collectis.com

Caitlin Kasunich
KCSA Strategic Communications
Phone: +1 212.896.1241
email: ckasunich@kcsa.com

Investor relations contact

Simon Harnest, VP Finance and Investor Relations
Phone: +1 646-385-9008
email: simon.harnest@collectis.com

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “intend,” “is designed to,” “may,” “might,” “plan,” “potential,” “predict,” “objective,” “should,” or the negative of these and similar expressions and include, but are not limited to, statements regarding the outlook for Collectis’ future business and financial performance. Forward-looking statements are based on management’s current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances, many of which are beyond Collectis’ control. Actual outcomes and results may differ materially due to global political, economic, business, competitive, market, regulatory and other factors and risks. Collectis expressly disclaims any obligation to update or revise any of these forward-looking statements, whether because of future events, new information, a change in its views or expectations, or otherwise.